Argos Therapeutics Inc. reported on an update on the interim analysis of data from the ongoing phase III ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma was presented by Robert Figlin, professor and chairman, division of hematology and oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial at the European Society for Medical Oncology 2017 Congress in Madrid.
Jonathan Chernoff and William G. KaelinWilliam G. Kaelin Jr., physician, scientist, and Nobel laureate, was recognized at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction.Â
